These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 3635565)

  • 21. C3 nephritic factor stabilization of the classic C3 convertase: a role for C2 in C3 nephritic factor activity.
    McLean RH; Nilson SH
    Proc Soc Exp Biol Med; 1979 Jul; 161(3):358-63. PubMed ID: 461464
    [No Abstract]   [Full Text] [Related]  

  • 22. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Non-specific immune mechanisms. The alternate pathway in the complement system].
    Schön K; Koeppe HW
    Med Klin; 1979 Mar; 74(13):461-9. PubMed ID: 431472
    [No Abstract]   [Full Text] [Related]  

  • 24. Generation of the classical pathway C3 convertase (EAC4b2a) by proteolytic enzymes.
    Loos M; Heinz HP
    Acta Pathol Microbiol Immunol Scand Suppl; 1984; 284():67-74. PubMed ID: 6375257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. C3 convertases of complement. Molecular genetics, structure and function of the catalytic domains, C2 and B.
    Volanakis JE
    Year Immunol; 1989; 4():218-30. PubMed ID: 2648703
    [No Abstract]   [Full Text] [Related]  

  • 26. [The complement system].
    Lambert PH
    Schweiz Med Wochenschr; 1975 Sep; 105(37):1180-4. PubMed ID: 1215899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clearances of complement components, C3 proactivator and other serum proteins in chronic membranoproliferative glomerulonephritis (CMPGN).
    Geiger H; Good RA; Day NK
    Clin Nephrol; 1975; 3(4):139-47. PubMed ID: 1149337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C4 binding protein deficiency in a patient with atypical Behçet's disease.
    Trapp RG; Fletcher M; Forristal J; West CD
    J Rheumatol; 1987 Feb; 14(1):135-8. PubMed ID: 3572915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of nephritic factor on C3 and on the terminal pathway of complement in vivo and in vitro.
    Mollnes TE; Ng YC; Peters DK; Lea T; Tschopp J; Harboe M
    Clin Exp Immunol; 1986 Jul; 65(1):73-9. PubMed ID: 3641694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of plicatic acid on human serum complement includes interference with C1 inhibitor function.
    Giclas PC
    J Immunol; 1982 Jul; 129(1):168-72. PubMed ID: 6979566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
    Kerr MA; Parkes C
    Biochem J; 1984 Apr; 219(2):391-9. PubMed ID: 6611150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary C2 deficiency and systemic lupus erythematosus associated with severe glomerulonephritis.
    Roberts JL; Schwartz MM; Lewis EJ
    Clin Exp Immunol; 1978 Feb; 31(2):328-38. PubMed ID: 348363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase.
    Burge J; Nicholson-Weller A; Austen KF
    J Immunol; 1981 Jan; 126(1):232-5. PubMed ID: 6778916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity, polypeptide chain composition and antigenic reactivity of autoantibodies (F-42) that are directed against the classical pathway C3 convertase of complement and isolated from sera of patients with systemic lupus erythematosus.
    Daha MR; Hazevoet HM; van Es LA
    Clin Exp Immunol; 1984 Jun; 56(3):614-20. PubMed ID: 6430610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoglobulin-independent utilization of the classical complement pathway in opsonophagocytosis of Escherichia coli by human peripheral leukocytes.
    Leist-Welsh P; Bjornson AB
    J Immunol; 1982 Jun; 128(6):2643-51. PubMed ID: 6210733
    [No Abstract]   [Full Text] [Related]  

  • 37. Complement activating cryoglobulins in the nephritis of systemic lupus erythematosus.
    Adu D; Williams DG
    Clin Exp Immunol; 1984 Mar; 55(3):495-501. PubMed ID: 6705265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Proteases in complement system (author's transl)].
    Nagasawa S
    Tanpakushitsu Kakusan Koso; 1980; 25(6):531-46. PubMed ID: 7010425
    [No Abstract]   [Full Text] [Related]  

  • 39. Modulation of the activity of the classical complement pathway C3 convertase by surface-bound C3 or C5.
    Strunk RC; Giclas PC
    J Immunol; 1980 Feb; 124(2):520-6. PubMed ID: 7356706
    [No Abstract]   [Full Text] [Related]  

  • 40. Steady state relations between control proteins regulating the formation of the alternative pathway C3 convertase.
    Reeve J; Woo PM
    Immunology; 1982 Aug; 46(4):859-66. PubMed ID: 6921154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.